Daly Caroline, Clemens Felicity, Lopez-Sendon Jose L, Tavazzi Luigi, Boersma Eric, Danchin Nicholas, Delahaye Francois, Gitt Anselm, Julian Desmond, Mulcahy David, Ruzyllo Witold, Thygesen Kristian, Verheugt Freek, Fox Kim M
Royal Brompton and Harefield NHS Trust, Royal Brompton Hospital, Sydney Street, and London School of Hygiene and Tropical Medicine, SW3 6NP, UK.
Eur Heart J. 2006 Jun;27(11):1298-304. doi: 10.1093/eurheartj/ehl005. Epub 2006 May 16.
The European Society of Cardiology published guidelines for the management of stable angina in 1997, with the objective of promoting an evidence-based approach to the condition. This study focuses on the impact of guideline compliant medical treatment on clinical outcome in patients with stable angina.
The Euro Heart Survey of Stable Angina is a multicentre prospective observational study conducted between 2002 and 2003. Patients with a clinical diagnosis of stable angina by a cardiologist were enrolled and follow-up was conducted at 1 year. The primary outcome of interest was death or myocardial infarction (MI). The increasing intensity of guideline compliant medical therapy was quantified by means of a simple treatment score based on the use of guideline advocated therapies: antiplatelets, statins, and beta-blockers. A total of 3779 patients were included in the initial survey. Increasing intensity of guideline compliant therapy at initial assessment was associated with a reduction in death and MI during follow-up in patients with angina and confirmed coronary disease (HR 0.68; 95% CI 0.49-0.95 per unit increase in treatment score). All cardiovascular events were also significantly reduced in this subgroup (HR 0.82; 95% CI 0.69-0.97). The benefits of guideline compliant therapy were only observed in patients with objective evidence of coronary disease.
Guideline compliant medical therapy improves clinical outcome in patients with stable angina and objective evidence of coronary disease.
欧洲心脏病学会于1997年发布了稳定型心绞痛管理指南,旨在推广基于证据的治疗方法。本研究聚焦于符合指南的药物治疗对稳定型心绞痛患者临床结局的影响。
欧洲稳定型心绞痛调查是一项于2002年至2003年开展的多中心前瞻性观察性研究。纳入经心脏病专家临床诊断为稳定型心绞痛的患者,并进行为期1年的随访。主要关注的结局是死亡或心肌梗死(MI)。基于使用指南推荐的疗法(抗血小板药物、他汀类药物和β受体阻滞剂),通过一个简单的治疗评分来量化符合指南的药物治疗强度的增加。初始调查共纳入3779例患者。在初始评估时,符合指南的治疗强度增加与心绞痛和确诊冠心病患者随访期间死亡和MI的减少相关(治疗评分每增加一个单位,风险比[HR]为0.68;95%置信区间[CI]为0.49 - 0.95)。该亚组中所有心血管事件也显著减少(HR 0.82;95% CI 0.69 - 0.97)。符合指南的治疗益处仅在有冠心病客观证据的患者中观察到。
符合指南的药物治疗可改善有稳定型心绞痛且有冠心病客观证据患者的临床结局。